Event-Driven Stocks

Ventyx Biosciences, Inc.

VTYX

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20
Revenue—————
Operating income−$148.4M−$208.0M−$113.1M−$67.1M−$7.0M
Net income−$135.1M−$193.0M−$108.4M−$83.7M−$28.2M
Total assets$276.6M$277.7M$371.4M$291.5M$245,000
Total liabilities$22.5M$33.8M$17.5M$12.3M$30.9M
Equity$254.0M$243.9M$353.9M$279.2M−$30.7M
EPS (diluted)$-1.97$-3.30$-2.07$-6.65—
Shares out.59.3M58.2M50.7M50.4M2.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−53.2%
Return on assets
−48.9%
Return on capital (ROCE)
−56.3%
Liabilities / assets
8.1%
Debt / equity
0.09×
Book value / share
$4.29
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
6.85safe
Accruals / assets
−1.5%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 3 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Feb 27, 20264.9M1.2+8.4%
Feb 13, 20264.5M1.6+4.1%
Jan 30, 20264.3M2.3-5.3%
Jan 15, 20264.5M1.0-37.7%
Dec 31, 20257.3M6.9+19.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)